The Shifting Treatment Landscape of Myeloma Market Beyond Darzalex: BI Replay

Join Bloomberg Intelligence (BI) analysts Sam Fazeli, Bethan Swift, and Cindy Wu as they unpack the findings from BI's proprietary Multiple Myeloma Disease Hub report. As novel therapies advance into earlier treatment lines, BI projects the global market will nearly double from $26 billion in 2026 to $47 billion by 2035. The forecast sees improved earlier-line patient survival shrinking later-line patient pools over time, despite rising diagnosis with aging demographics. In this webinar, BI analysts will break down shifts across the treatment landscape, where dynamics feed into BI's epidemiology and sales modeling.